Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budesonide + prednisone + salmeterol
- Development stage
- Unknown
- Lead developer
- SMB Laboratories
- Modality
- Small Molecules
- Administration
- Inhalation, Oral
01
Overview
This is a combination of three medications: budesonide (an inhaled corticosteroid), prednisone (an oral corticosteroid), and salmeterol (a long-acting beta-agonist). Budesonide works by preventing inflammation in the lungs, while salmeterol is a bronchodilator that opens up the air passages in the lungs. Prednisone is a systemic corticosteroid that reduces inflammation throughout the body. This combination might be used in severe asthma cases requiring both inhaled and systemic corticosteroids along with a long-acting bronchodilator.
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on budesonide + prednisone + salmeterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budesonide + prednisone + salmeterol.